Treatment discontinuation and tolerability as a function of dose and titration of duloxetine in the treatment of major depressive disorder

Código QR

Treatment discontinuation and tolerability as a function of dose and titration of duloxetine in the treatment of major depressive disorder

Eiji Harada,1 Osamu Shirakawa,2 Yoichi Satoi,3 Lauren B Marangell,4 Rodrigo Escobar5 1Eli Lilly Japan K.K., Medicines Development Unit Japan, Medical Science, Kobe, 2Department of Neuropsychiatry, Kinki University Faculty of Medicine, Osakasayama, 3Eli Lilly Japan K.K., Medicines Development Unit J...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Harada E, Shirakawa O, Satoi Y, Marangell LB, Escobar R
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	antidepressant dose duloxetine major depressive disorder titration Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/605ed851076645a6ab46bdc7d4e1a89b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Functioning in patients with major depression treated with duloxetine or a selective serotonin reuptake inhibitor in East Asia
por: Novick D, et al.
Publicado: (2016)

Stimulus intensity determined by dose-titration versus age-based methods in electroconvulsive therapy in Thai patients
por: Ittasakul P, et al.
Publicado: (2019)

Maintaining efficacy in the treatment of diabetic peripheral neuropathic pain: role of duloxetine
por: Russell J, et al.
Publicado: (2010)

Escitalopram vs duloxetine in acute treatment of major depressive disorder: meta-analysis and systematic review
por: Maneeton B, et al.
Publicado: (2018)

Comparison of duloxetine and SSRI as a treatment option of painful physical symptoms associated with major depressive disorder
por: Haider M, et al.
Publicado: (2017)

Update on duloxetine for the management of stress urinary incontinence
por: Maya Basu, et al.
Publicado: (2008)

Analysis of HAM-D scores and working ability in an observational study of Japanese patients with major depressive disorder and painful physical symptoms treated with duloxetine or SSRI monotherapy
por: Kuga A, et al.
Publicado: (2019)

Efficacy and Safety of Cordyceps militaris as an Adjuvant to Duloxetine in the Treatment of Insomnia in Patients With Depression: A 6-Week Double- Blind, Randomized, Placebo-Controlled Trial
por: Jiaojiao Zhou, et al.
Publicado: (2021)

An observational study of duloxetine versus SSRI monotherapy for the treatment of painful physical symptoms in Japanese patients with major depressive disorder: primary analysis
por: Kuga A, et al.
Publicado: (2017)

Efficacy comparison of duloxetine and SSRIs at doses approved in Japan
por: Harada E, et al.
Publicado: (2015)

EFFICACY AND SAFETY OF DULOXETINE IN THE TREATMENT OF CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY: A SYSTEMATIC REVIEW AND META-ANALYSIS
por: I Putu Eka Widyadharma, et al.
Publicado: (2021)

An observational study of duloxetine versus SSRI monotherapy in Japanese patients with major depressive disorder: subgroup analyses of treatment effectiveness for pain, depressive symptoms, and quality of life
por: Kuga A, et al.
Publicado: (2017)

Clinical meaningfulness of duloxetine's effect in Chinese patients with chronic pain due to osteoarthritis: post hoc analyses of a phase 3 randomized trial
por: Yue L, et al.
Publicado: (2019)

Efficacy and Safety of a Decision Support Intervention for Basal Insulin Self-Titration Assisted by the Nurse in Outpatients with T2DM: A Randomized Controlled Trial
por: Hu X, et al.
Publicado: (2021)

Comparative effectiveness of switching paroxetine formulation for treatment of major depressive disorder: an open-label multicenter study
por: Otsubo T, et al.
Publicado: (2018)

Evaluating the Effect of Preoperative Duloxetine Administration on Postoperative Pain in Patients under Abdominal Hysterectomy
por: H Sattari, et al.
Publicado: (2020)

COMPARATIVE STUDY OF EFFECTIVENESS OF VENLAFAXINE, DULOXETINE AND SERTRALINE IN MANAGEMENT OF DIABETIC SENSORY NEUROPATHY
por: Nabila Shaukat, et al.
Publicado: (2021)

Treatment response in relation to subthreshold bipolarity in patients with major depressive disorder receiving antidepressant monotherapy: a post hoc data analysis (KOMDD study)
por: Park YM, et al.
Publicado: (2016)

Clinical Pharmacist’s Intervention to Improve Medication Titration for Heart Failure: First Experience from Sudan
por: Ahmed KO, et al.
Publicado: (2021)

Mind your state: Insights into antidepressant nonadherence
por: De Wet Wolmarans, et al.
Publicado: (2016)

Cognitive impairment in depression: recent advances and novel treatments
por: Perini G, et al.
Publicado: (2019)

The noradrenergic paradox: implications in the management of depression and anxiety
por: Montoya A, et al.
Publicado: (2016)

Brain Targeting of Duloxetine HCL via Intranasal Delivery of Loaded Cubosomal Gel: In vitro Characterization, ex vivo Permeation, and in vivo Biodistribution Studies
por: Elsenosy FM, et al.
Publicado: (2020)

Efficacy and safety of multiple doses of levomilnacipran extended-release for the treatment of major depressive disorder
por: Huang Q, et al.
Publicado: (2016)

Clinical and Neurocognitive Predictors of Functional Outcome in Depressed Patients with Partial Response to Treatment: One Year Follow-Up Study
por: Castellano S, et al.
Publicado: (2020)

Early symptom non-improvement and aggravation are associated with the treatment response to SSRIs in MDD: a real-world study
por: Yuan H, et al.
Publicado: (2019)

Heterogeneity in diabetic distal neuropathy and differential approach to its treatment
por: Oksana Evgen'evna Khutornaya, et al.
Publicado: (2013)

Escitalopram versus paroxetine controlled release in major depressive disorder: a randomized trial
por: Kishi T, et al.
Publicado: (2017)

Is Agomelatine Associated with Less Sedative-Hypnotic Usage in Patients with Major Depressive Disorder? A Nationwide, Population-Based Study
por: Hsing SC, et al.
Publicado: (2020)

Use of antidepressants in the treatment of major depressive disorder in primary care during a period of economic crisis
por: Sicras-Mainar A, et al.
Publicado: (2015)

The Relationship Between Baseline Clinical Symptom Characteristics and Working Ability in Japanese Patients Treated for Major Depressive Disorder and Painful Physical Symptoms
por: Sugawara N, et al.
Publicado: (2020)

Duloxetine in the treatment of generalized anxiety disorder
por: Trevor R Norman, et al.
Publicado: (2009)

The role of duloxetine in the treatment of anxiety disorders
por: Domenico De Berardis, et al.
Publicado: (2008)

Patient Expectations and Experiences of Antidepressant Therapy for Major Depressive Disorder: A Qualitative Study
por: Baune BT, et al.
Publicado: (2021)

Glycogen Determination in Bovine Muscle: A Proposal for Rapid Determination
por: Hargreaves B,Antonio, et al.
Publicado: (2009)

Ethanol in low chronic dose level attenuates major organic effects in malnourished rats
por: AGUIAR,ALINE S DE, et al.
Publicado: (2009)

Does early improvement in depressive symptoms predict subsequent remission in patients with depression who are treated with duloxetine?
por: Sueki A, et al.
Publicado: (2016)

Association of VEGF With Antianhedonic Effects of Repeated-Dose Intravenous Ketamine in Treatment-Refractory Depression
por: Wei Zheng, et al.
Publicado: (2021)

Initial Treatment Response in Ocular Myasthenia Gravis: A Comparison Between Low and Moderate Doses of Prednisolone
por: Threetong T, et al.
Publicado: (2020)

Optimized regimens of combined medications for the treatment of major depressive disorder: a double-blind, randomized-controlled trial
por: Zuilhof Z, et al.
Publicado: (2018)